Suggested remit: To appraise the clinical and cost effectiveness of 177Lu-PSMA-617 within its marketing authorisation for treating prostate-specific membrane antigen (PSMA) positive, hormone-relapsed metastatic prostate cancer previously treated with androgen receptor directed therapy (ARDT) and taxane based chemotherapy.
 
Status In progress
Process STA 2018
ID number 3840

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 08 June 2021 - 06 July 2021
In progress. DHSC referral received 01 September 2021

Project Team

Project lead Michelle Adhemar

Email enquiries


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance